Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Plus Sorafenib Compared With Transarterial Chemoembolization Plus Sorafenib in Patients With BCLC C Stage Hepatocellular Carcinoma

NCT02856126 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT02856126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02856126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Plus Sorafenib Compared With Transarterial Chemoembolization Plus Sorafenib in Patients With BCLC C Stage Hepatocellular Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2016
Completion date
July 31, 2024
Enrollment
214 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma